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The aim of this thesis has been to investigate the use of cannabinoids in treatment of epilepsy.  
The idea came from the rising in attention in publicity and social media to patients with 
intractable epilepsy, that tried some sort of cannabinoid treatment with a positive outcome. These 
types of compounds have been regarded as without medicinal potential during most of the 20th 
century and due to political reasons, they have been hard to study. However, with the increasing 
number of anecdotal cases that showing encouraging results, there has been a resurging interest 
in cannabinoids.  
 
Therefore, we set out to review the latest literature within the subject and also to perform an 
international survey to explore the knowledge and experience of caregivers in some countries of 
Northern Europe.  
 
I would like to thank Thorstein Gerstner, Helle Hjalgrim, Jakob Bie Granild-Jensen, Björn 
Bjurulf, Martin Jägervall and Roland Flink who helped us distribute the survey! I would also like 
to thank Claus Klingenberg a lot, for being my supervising professor in writing this thesis. He 
has contributed with both theoretical and clinical knowledge, and motivational support! There 
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Background: The aim for this thesis has been to investigate the use of cannabinoids in treatment 
of epilepsy. The topic is currently under a lot of discussion in many countries, and there is a high 
pressure on the health community to make these substances available from both patients, their 
families and politicians. This thesis consists of two parts. First, I aimed to review the literature 
on this topic over the last 5 years. Secondly, we performed an international survey to investigate 
how much knowledge, clinical experience or perhaps lack or experience caregivers have on this 
topic.  
Material and Methods: Clinical and medical databases were searched and the studies that 
matched inclusion/exclusion criteria were analysed. A web-based survey was sent out to neuro-
paediatricians in Norway, Sweden, Denmark and Germany. 
Results: The results from the literature show that especially cannabidiol (CBD) has an effect on 
seizure reduction, mainly shown in people with treatment resistant epilepsy (TRE). 
We received response from 86 neuro-paediatricians, a low response rate (~14 % ). Therefore, one 
can question how representative the results of the survey results are. However, the results 
indicate that a majority of caregivers argue that they do not treat patients that are in need of this 
treatment. Another issue seems to be that there is no product available, but mostly they also 
warrant studies to prove safety and efficacy. However, a lot of caregivers have come into contact 
with patients/families that have requested CBD treatment.   
Conclusion: More placebo-controlled studies of CBD are needed, where it is also taken in 
account for these drug-drug interactions that have been shown and that there might be certain 
subgroups of epilepsy that benefit more than others.   
The low response rate in our survey may indicate low interest for the topic. Or perhaps it will 












It is estimated that  > 50 millions of people live with epilepsy globally. That represents ~0.7% 
of the world’s population, and 0.5 % of the total disease burden in the world. However, the 
incidence of epilepsy is not evenly distributed in the population. It is more prominent in 
people below 20 years and over 60 years, and also in people in developing countries (1, 2). 
Epilepsy was in the 1850s redefined as a neurological disease even though it was still 
considered a psychiatric condition. Today epilepsy is no longer considered to be a psychiatric 
condition but as a chronic neurological condition (1). 
Different antiepileptic drugs (AEDS) are used to treat epilepsy, and many patients 
respond favourably. However, most AEDs have different adverse effects that have been found 
to impact quality of life. Retention rates have been shown to be equal among first and second-
generations AEDs, despite different side effect profiles. Many parents express specific 
concern about cognitive side effects of AEDs (3). 
Among children with epilepsy, there exist a subset of patients whose families are 
choosing to pursue alternative therapies, either instead of or in combination with conventional 
AEDs. Many of these patients have refractory epilepsy and have failed to gain control of their 
seizures after trials of many medications and interventions. Oral cannabis extracts (OCEs) are 
being used in the treatment of epilepsy with increasing rates in the United States following 
product legalization. However, the scientific documentations of clinical efficacy of OCEs has 
been limited or absent (3). 
 
1.2  Definition of Epilepsy  
Epilepsy is defined as an ongoing neurological condition that is characterised by spontaneous 
recurring high-frequent synchronised overexcitation in the brain that is manifested as a 
periodic seizure (1, 2). In an instruction manual for operational classification of seizures by 
Fischer et. al in 2017 , seizures are generally divided depending on onset. Focal onset, 
generalized onset and unknown onset are described. Subcategories like motor (convulsive) or 
non-motor component, awareness or impaired awareness and absence are a few of them.  




Most people think of generalized tonic-clonic seizures when they think of epileptic 
seizures, and they may be characterised by convulsions. However, epileptic seizure attacks 
without obvious (motor) convulsions are also common. There can be a lot of different types 
of combinations of seizures, and some seizures types, for example tonic seizures or epileptic 
spasms, can have either a focal or generalized onset. Also, level of consciousness or altered 
consciousness is a confusing concept even though central to many seizures (1, 4), 
In a 2015 a new definition of status epilepticus (SE) was presented by The 
International League Against Epilepsy (ILAE) (5). SE was considered as a condition resulting 
from the failure of the mechanisms responsible for seizure termination or from the initiation 
of mechanisms, which lead to abnormal, prolonged seizures. It is a condition, which can have 
long-term consequences, including neuronal death, neuronal injury, and alteration of neuronal 




   1.2.1. Epidemiology of Epilepsy  
Epilepsy is one of the world’s oldest recognized conditions, with written records dating back 
to 2800 BC in China (6). More than 50 million people worldwide have epilepsy, globally 2.4 
million people are diagnosed with epilepsy each year. Epilepsy is a chronic disorder of the 
brain that effects people of all ages. In high-income countries, annual new cases are between 
30-50 per 100.000 people. In low and middle-income countries these numbers can be up to 
two times higher (2). Six out of 10 people with epilepsy (PWE) have idiopathic epilepsy, with 
no identifiable cause. Epilepsy with a known cause is called secondary, or symptomatic 
epilepsy.  Secondary causes can be: 
- brain damage from prenatal or perinatal injuries (e.g. a loss of oxygen or trauma during 
birth, low birth weight). 
- congenital abnormalities or genetic conditions with associated brain malformations. 
- a severe head injury. 
- a stroke that restricts the amount of oxygen to the brain. 
- an infection of the brain such as meningitis, encephalitis, neurocysticercosis. 
- certain genetic syndromes.  
- a brain tumour.  





   1.2.2. Treatment of Epilepsy 
There are a number of treatments for epilepsy. Around 70% of PWE can be successfully 
treated with AEDs and get seizures under complete control. Furthermore, after 2 to 5 years of 
successful treatment and being seizure-free, drugs can be withdrawn in about 70% of children 
and 60% of adults without subsequent relapse. 
Globally there is a “treatment gap”. In low- and middle-income countries, about ¾ of 
PWE may not receive the treatment they need. Although it is possible to diagnose and treat 
most PWE at the primary health-care level without the use of sophisticated equipment (2). 
There are also some of the non-pharmacological treatment options such as ketogenic diet 
(KD), vagus nerve stimulation (VNS) and surgery (resective surgery, corpus callosotomy 
etc.). These treatment modalities have all been shown to be effective in selected patients.  
Most AEDs have adverse effects that have been found to impact quality of life. 
Patients with treatment-resistant epilepsy (TRE) have often tried many different AEDs and 
risk both interactions and more adverse effects. Many parents express specific concern about 
cognitive side effects of AEDs (3).  
 
   1.2.3. Treatment-resistant epilepsy (TRE) 
Approximately 30 % of PWE have refractory seizures even though they are on an 
“optimized” regimen with AEDs. There is however no currently valid definition of TRE. 
Usually when two separate medications have been tried, and you still have not achieved 
satisfactory treatment for the patient, they are referred to specialized care for further 
investigation. Although the number of AEDs on the market has continuously increased, it is 
not reflected in better control of seizures in patients with TRE (1). Even with all the different 
therapy available, less than 10% of patients with TRE become seizure free (7). 
 
I will here present three different epileptic syndromes that often show treatment-resistance: 
• Dravet syndrome (DS), is a rare genetic form of epileptic encephalopathy, primarily due 
to loss-of-function mutations in the SCN1A-gene. It was described in 1978 by Charlotte 
Dravet. DS typically presents around 5-8 months of age with febrile seizures that progress 
to severe partial or generalized tonic-clonic seizures, and episodes of status epilepticus. It 




in voltage-gated sodium channel type 1 (NaV.1.1) causing impaired firing of GABAergic 
interneurons, which results in an imbalance between excitation and inhibition that leads to 
seizures. The treatment of DS is generally combinations of AEDs and KD, but a large 
number remain treatment resistant (8). 
• Lennox-Gastaut syndrome (LGS) is also a rare, severe form of epileptic encephalopathy 
with early childhood onset, usually manifests by 8 years with peak incidence between age 
3-5. Patients are frequently treatment resistant to available medications. It is characterised 
by the occurrence of multiple seizure types, including so-called drop attacks (atonic, tonic, 
tonic-clonic seizures), slow spike-and-wave activity on electroencephalograms, and 
cognitive impairment. Few robust, population-based epidemiological studies of Lennox-
Gastaut syndrome have been done, but regional studies (4-5) have reported that Lennox-
Gastaut syndrome accounts for 1-4% of cases of paediatric epilepsy (7). 
• Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder with 
highly variable expression. TSC is caused by a mutation in the TSC1 and TSC2 genes, 
which encode for the hamartin and tuberin proteins, respectively. Normally, these proteins 
form a complex that acts as a tumour suppressor and a central regulator in the mammalian 
target of rapamycin (mTOR) signalling cascade. TSC is characterized by the presence of 
hamartomas in almost every organ system, including tubers and subependymal nodules in 
the brain (9). The most common neurologic symptom of TSC is epilepsy, which affects 
approximately 85 % of patients. Approximately 63 % develop treatment-resistant epilepsy 
(as opposed to 23% in the general epilepsy population). Around 8 in 10 experience their 
first seizure within the first 3 years of life, and 5 in 10 have more than one seizure type 
(9). 
 
1.3.   Cannabinoids 
Derivates from the cannabis plant, Cannabis sativa, have long been used as a treatment for 
many disorders, from anorexia to pain. Ancient reports from early civilizations suggest that 
cannabis extracts can reduce seizures and was used from ~2800 BC in China until mid-1800s. 
in the western civilization (6). 
There has recently been more attention paid to medical marijuana, in particular to 
strains that are high in cannabidiol (CBD) and low in tetrahydrocannabinol (THC), for the 




anticonvulsant properties. Independent action on endogenous receptors and ion homeostasis 
has been demonstrated (3), (10). 
Chronic exposure to marijuana is associated with poorer cognitive outcomes, however 
there are few data available on the impact of chronic exposure to specific marijuana derivate 
products, especially in patients who already have cognitive delays (3). 
 
   1.3.1. Definition of cannabinoids 
Cannabinoids can be defined as substances that bind to and activate the endocannabinoid 
receptors in the body. Cannabinoids are divided into i) phyto-cannabinoids, ii) endo-
cannabinoids and iii) synthetical cannabinoids. Phyto-cannabinoids are extracted from the 
cannabis plant (cannabis sativa), endocannabinoids are produced in the body (Anandamide, 2-
arachidonoyl-glycerol etc.) and synthetical cannabinoids are produced in laboratories (11). 
Cannabis extract contains a numerous of related effective substances, which are called 
cannabinoids. The two substances that are found in largest quantity is ∆^9-
tetrahydrocannabinol (THC) and its precursor Cannabidiol (CBD). CBD does not possess the 
psychoactive traits of THC and has shown anticonvulsive characteristics (11). Several 
preclinical and clinical studies suggest that CBD has anticonvulsant effects and is well 
tolerated (6), (12, 13). 
 
1.3.2. Endocannabinoid receptors 
The body’s endocannabinoid receptors are part of the endocannabinoid system. The 
cannabinoid receptors are divided into CB1 receptor (CB1R) and CB2 receptor (CB2R). The 
CB1Rs are mostly localised in the central nervous system, while the CB2Rs are mostly 
localised in peripheral tissue. Both these receptors are G-protein coupled receptors (11). 
There are large amounts of CB1Rs in the brain, with similar numbers of receptors for 
glutamate and GABA – which are the central excitatory and inhibitory neurotransmitters. 
CB1Rs in the brain are found primarily in the hippocampus, hypothalamus, cerebellum, the 
mesolimbic dopamine system, substantia nigra and cerebral cortex. Activation of the CB1R is 
what gives the psychoactive effects. CB1R is also found in peripheral tissue such as 
adipocytes, endothelial cells, and peripheral nerves. There is only a small amount of CB1R in 
the brainstem, which matches clinical findings that cannabinoids do not affect respiratory and 




CB2R is found primarily in lymphatic tissue, such as the tonsils, spleen and 
lymphocytes that circulates the bloodstream. CB2Rs can also be found in the central nervous 
systems immune cells that are called microglia (11). 
 
1.3.3. Presumed mechanisms of cannabinoids in the epileptogenesis 
In the frontal lobe of the cerebrum there are large connected networks that can generate 
synchronised neural activity. However, if such activity occurs in excess in the cortical, 
hippocampal or thalamocortical networks, this can lead to epileptogenesis. The activity can 
also cause persisting changes in these neural networks which then can cause hyperexcitability, 
which we know as the pathology epilepsy (14). The endocannabinoid system is therefore an 
attractive target for therapeutic purpose since it has been shown that activation of it can affect 
the synaptic transmission between these neurons and thereby regulate the hyperexcitation 
within these networks (1). It has been shown that epilepsy modifies the endocannabinoid 
system (e.g. the CB1 receptor).  Activation of CB1R, may as many other neuromoduling 
systems enhance or inhibit the time of seizures. Depending on the neuronal subpopulation 
involved (15).  
In experiential models one has to be very certain on which type of neurons that are 
being observed/studied, to be able to determine whether CB1R in those specific surroundings 
show proconvulsive or anticonvulsive traits. It has become clear that CB1R is functional and 
is participating actively in the modulation and thereby regulation of epileptogenesis. With this 
knowledge, it also becomes possible to map down the anticonvulsive effect that cannabinoids 
have, also on different types of human epilepsy (14, 15). 
Even though the results from the experimental models are relevant for the 
understanding of endocannabinoids role in epileptogenesis, they do not fully recreate the 
pathological conditions that occur in PWE. To study cerebral tissue collected from patients 
with TRE, which is made possible due to patients having  epileptic surgery can be essential in 
the investigation of cannabinoids and the endocannabinoid system as therapeutic targets for 
PWE (15). 
Research on the endocannabinoid system and its part in protecting neurons from 
developing epileptic pathology in animals, has provided us with new knowledge. Also, the 
long history of usage of extracts from cannabis plants might suggest that it could have anti-





2. Aim of the study 
There are two aims of this thesis:  
 
• Firstly, to review the literature over the last five years aiming to assess whether 
cannabinoids may have a role in treatment of epilepsy.  
 
• Secondly, to perform a web-based survey aiming to obtain knowledge about clinical 
experience and perceptions on cannabinoid use for epilepsy among neuro-paediatricians in 
Norway, Sweden, Denmark and Germany. 
    
 
3. Method and material  
 
3.1. Literature review  
My aim was to review literature published last 5 years on cannabinoid therapy for epilepsy. I 
used the PRISMA protocol for a systematical approach (16).  
 
3.1.1. Criteria for including/excluding literature 
 
Inclusion and exclusion criteria were determined for the review. 
 
Inclusion criteria: Firstly, I included literature of clinical effects, animal trials and 
pharmacological of cannabinoids being used for studying anti-convulsive traits. Secondly, in 
order to get updated knowledge and to avoid too many articles we aimed for articles I 
included only articles published last 5 years. 
Exclusion criteria: Articles about recreational cannabis smoking. Articles about cannabinoids 
used in other fields of medicine, such as pain control in multiple sclerosis or palliative cancer 
treatment. Articles focusing on the psycho-activity of different cannabinoid substances.
 
 




Using the PICO model for clinical questions, we defined what subjects on which our searches 
were to be performed (17). Epilepsy and children was the group of patients that were targeted. 
The intervention that we wanted to investigate was cannabinoid therapy.  
The three subjects were defined to be cannabinoids, epilepsy and child. After these were 
confirmed, a couple of appropriate databases were identified in which searches on our three 
subjects firstly were performed on the individual subject, then cross referenced so that the 
result of our search would include our 3 subjects.  
 
I performed searches in two databases: Ovid’s MED-LINE and Ovid’s EMBASE. The 
searches were performed on several occasions, but the last one was performed on the 06.04.18 
on both MED-LINE and EMBASE.  
 
 
3.2.  International survey  
As part of the thesis, a survey was also outlined on the topic of cannabinoid treatment of 
epilepsy in children. Our aim was to send it to neuro-paediatricians in Norway, Sweden, 
Denmark and Germany. We got help from colleagues in these specific countries for the 
distribution.  
It is a short survey (16 questions, takes less than 5 min to answer) with the purpose of 
exploring and trying to map how much knowledge, clinical experience (or lack of experience) 
caretakers have about cannabinoids as treatment of epilepsy. We also asked to what extent 
patients (or families) have asked, for these kinds of treatments. Another interest point was if 
the caretakers had knowledge of patients with epilepsy self-medicating with cannabinoids. 
We used the online survey software Survey Monkey®. The system gathered the responses and 
produced analysis of the data. See survey attached.   
 
4. Results  
Literature review 
In MED-LINE 111 articles were found in the cross-referenced search and 51 articles matched 
the inclusion criteria. In EMBASE 39 articles were found when the search was performed, 
and 11 were included after matching our inclusion criteria. In total with our two databases 




of reviews, brief communication that was used for background information and literature in 
books, that describe cannabinoids pharmacological mechanism’s in relation to 
epileptogenosis, which are also used in the introduction.   
 
The results of the literature review is presented according to the study design. 
Randomised clinical trials (RCT) present strongest evidence, prospective cohort studies 
provide less strong evidence, and retrospective cohort studies or case-control studies provides 
lower quality of evidence. Cannabinoids effect are of interest despite not reporting clinical 
outcomes in human patients. 
 2 RCTs, 6 prospective cohorts, 3 retrospective cohorts, 9 animal/pharmacological 
studies and 5 international surveys were reviewed. 
 
 
4.1.1 Clinical Trials 
There were two RCTs published last 5 years. Both studies were multinational, double-blinded 
phase III trials. The trials consisted of one treatment group that got adjunctive CBD on top of 
their epilepsy treatment regimen versus a placebo group. The populations were DS patients 
(Devinsky, et al. 2017) and LGS patients (Thiele et al, 2018)  (7, 18). 
Their results for their primary endpoint indicated that CBD as an ad-on therapy was 
successful in reducing convulsive seizures. Other secondary endpoints, like quality of life, 
alertness and sleep pattern also was reported by their caregivers to be improved. In the LGS 
study there were 3 times as many patients/caregivers in the CBD group that reported 
improvement in the secondary endpoints than the placebo group. Some patients could also 
reduce their use of AEDs, however this was not only because of positive results of the therapy 
but also because of drug-drug interactions between some AEDs and CBD (7, 18). 
During the treatment period three patients in the CBD group and no patients in the 
placebo group were free of seizures (P=0,08) in the DS-study (18). In the LGS-study three 
patients who were in the CBD group and completed treatment were drop-seizure free 
throughout the 12-week maintenance period (7). No patients in the placebo group were free of 
drop seizures in either studies (7, 18).  
There were also some adverse effects which were more prominent in the CBD group 




were mild or moderate in severity (diarrhoea, somnolence, pyrexia, decreased appetite and 
vomiting), however some serious adverse events occurred (7, 18). 
In the DS study, status epilepticus was reported in three patients in each group, 
elevated levels of liver enzymes led to the withdrawal from the trial for three patients in the 
CBD group and 1 in the placebo group. All patients with elevate levels of liver enzymes were 
taking some form of valproate (18). 
Sensitivity analyses from the LGS study confirmed that the treatment effect of cannabidiol on 
the primary endpoint was established during the first 4 weeks of the maintenance period and 
was maintained during the full treatment period. Sensitivity analyses of the three key 
secondary endpoints also showed significant treatment differences in favour of CBD (7). 
 
Other clinical studies 
I identified nine open-label prospective and retrospective cohort studies published between 
2013-2018. Almost all of them focus on different specific epileptic syndromes, and how CBD 
(Epidiolex®, GW Pharmaceuticals) or some other compound that is high in CBD and low in 
THC affects seizure control and quality of life. Many of the patients used several AEDs and 
other non-pharmacological treatments but still did not achieve seizure control (3, 9, 10, 19-
22). I will present five of these studies in detail, and the last four only briefly in Table 1. 
 
In one prospective cohort study (Hess et al, 2016, 18 patients who had TSC (TSC1 or TSC2 
mutation) were followed. The primary endpoint was total weekly seizure frequency change. 
Patients were defined as responders if they had a > 50% reduction in total seizure frequency. 
After 3 months of CBD-treatment, there was a median 50% reduction in seizure frequency. 
Moreover, four patients had a  > 80% decrease in seizures and two patients had 90 % seizure 
reduction. Most adverse effects experienced in this study were temporary and of mild 
severity. Adverse effects were resolved through dose adjustments of CBD or concomitant 
antiepileptic drugs. The most common adverse effects cohere with profiles in other studies 
(9). 
 
In one retrospective cohort study (Treat et al, 2017), oral cannabis extracts (OCEs) duration 
and discontinuation was measured in relation to perceived benefit by parents. Seizure 
response was based on a parental report of seizure frequency prior to initiating OCEs 




included, 24% were considered to be responders to OCE treatment. LGS was the only 
syndrome type associated with a significantly higher proportion of responders when 
compared to all other patients in the cohort: 11 (58%) of 19 patients (p < 0.05). Perception of 
seizure benefit was shown to be the only significantly associated factor with longer duration 
of OCE use (p < 0.01). The only syndrome that emerged to have a significant impact on 
duration of OCE use (p=0.02) was DS, which was associated with a shorter duration of OCE 
use. Adverse events due to OCE treatment were reported by parents of 23 patients (19%). The 
presence of adverse events was significantly associated with faster discontinuation of OCE 
treatment (p = 0.03). Eighty-four patients (71%) discontinued their OCE use during the study 
period (3). 
 
In another open label interventional (Devinsky et al. 2016) trial patients with severe, 
childhood-onset TRE were studied at 11 epilepsy centres across the US. The most common 
epilepsy syndromes treated were DS and LGS. The primary endpoint was to establish the 
safety and tolerability of CBD, and the primary efficacy outcome was median percentage 
change in the mean monthly frequency of motor seizures at 12 weeks. The median change in 
total seizures was –34.6% (IQR –66,7 to –9,8). Two patients were free of all seizure types 
over the entire 12 weeks. Analysis of the secondary endpoints of responder rates showed that 
54 (39%) patients had a reduction of 50% or more motor seizures. Most adverse events were 
mild or moderate and transient. Serious adverse events were reported in 48 (30 %) patients. 
Serious adverse events deemed possibly related to CBD use were recorded in 20 patients and 
included status epilepticus, diarrhoea, pneumonia, and weight loss. Eleven (7%) patients had 
elevated liver function tests, one patient had a significant increase in transaminases leading to 
discontinuation of CBD. The adverse event profile of CBD was favourable, with most 
patients tolerating the drug well despite its addition to a median of three concomitant 
antiepileptic drugs (10) 
 
In an observational, longitudinal study (Hausman-Kedem et al. 2018) the effect of 
cannabinoids on TRE was assessed. Forty-six patients were included in the efficacy analysis. 
56% had a reduction of 50% or more in all seizure types. 19 patients partially or completely 
tapered 1-3 AEDs. AEs occurred in 46 % of patients. Improvement of AEs came with time or 
dose reduction. A beneficial response such as improvement in behaviour, communication, 




An expanded access investigational new drug study (Geffrey AL, et al, 2015) focused on the 
safety and efficacy of CBD (Epidiolex®, GW Pharmaceuticals) as a new adjuvant treatment 
for refractory epilepsy in 25 children. Pharmacokinetic analysis of clobazam (CLB) in 
previous clinical trials has demonstrated that there is a clinically significant drug-drug 
interaction when CLB is taken with strong or moderate CYP 2C19 inhibitor. Interaction 
between CBD and CLB in the 13 children who are taking both drugs concomitantly was also 
evaluated. Nine of the 13 subjects had a > 50% decrease in seizures, corresponding to a 
responder rate of 70%. Over the course of CBD treatment, CLB dose were reduced for 10 
(77%) of the 13 subjects. The mean change in seizure frequency for the 10 subjects with 
lowered CLB doses was a 50 % decrease, whereas the mean change for those without was a 
55% decrease. Side effects were reported in 10 (77%) of the 13 patients. These 10 subjects 
experienced drowsiness (n=6), ataxia (n=2), irritability (n=2), restless sleep (n=1), urinary 
retention (n=1) and loss of appetite (n=1). All side effects were resolved with CLB dose 
adjustments. All study objects continued to tolerate CBD well at time of data analysis (week 
36 of treatment (23). 
 
Table 1 shows four more clinical studies made between 2013-2018. 
 
4.1.2. Pharmacological studies and Animal Trials 
The antiepileptic mechanisms of CBD have not been fully elucidated and is considered to be 
mediated by inhibiting excitatory glutamatergic neurotransmission, mostly via cannabinoid 
receptor-independent mechanisms. Other properties of CBD, including neuroprotective, anti-
inflammatory and antioxidant properties have been described (24). Nine studies investigating 
CBD-pharmacology studies or animal CBD studies are described in Table 2 (8, 25-32). 
 
4.1.3 Previously published international surveys 
Five publications from surveys relative to the topic were identified in our searches (33-37). 
The surveys were constructed seeking opinion, knowledge and experience from PWE, their 
families or caregivers about usage of cannabis products in treatment of epilepsy. They were of 
different sample sizes, patients used different kind of cannabis products (e.g. CBD-enriched 
cannabis, Real scientific hemp oil = RSHO-X ® ) and took place in different countries (e.g. 




medical agencies, this of course makes a difference in how easy it is to purchase products and 
knowing the quality of them. 
Web-based application were mostly used to collect the survey data (REDCap, 
SurveyMonkey® etc.). Some of the surveys had clear endpoints defined, e.g. response rate of 
> 50% seizure rate, whilst other just reported a reduction of seizure frequency not specifying 
how big the rate of seizure reduction was. In general, the results from the surveys were 
positive, and benefits in quality of life, emotional state, communication, sleep patterns and 
diet were also reported.  
One of the studies tried to identify predictors for cannabis use and against. Here the 
number of past used AEDs was a significant predictor of cannabis product use, and the 
uncertainty of the product quality and how to get at hold of it was a predictor against use. 
However, over 55% of the study sample reported willingness to participate in medical 
research studies in medicinal cannabis (33-37).  
 
4.2. International survey on cannabinoid treatment of epilepsy 
in children. 
Our survey was sent out to neuropaediatricians in four countries. 300 members in the neuro-
paediatric association in Sweden, 149 neuro-paediatricians in German, 124 members of the 
neuro-paediatric association in Denmark and 50 neuropaediatricians in Norway. We got 85 
responses in total witch gives us a response rate of 13.6%.  
The responders were almost equally distributed in gender with 42 females (49.4%) and 
43 males (50.6%). Also, the distribution of responses in regard to country of practice were 
representative (although low response rate). Table 3 shows how the responders age and Figure 
2 the responder’s country of practice. 
The work experience generally in the field of neuropediatric was high, almost half of 
them had over 15 years of experience. Fifty-six out of 85 responders (66%) answered that 
they treat children with epilepsy at least every week. Moreover, 80 caregivers (96%) had 
heard about of the use of cannabinoids in treating epilepsy in children. Forty-seven (60%) 
knew that CBD is the component of cannabinoids that is suggested to be most important for 
anti-epileptic activity. Only ten caregivers had personally prescribed cannabinoids for 
treatment of children with epilepsy, which was 12% out of the 80 who responded to the 




asked for their reasons (Figure 3). In open field answer the most frequent response, was that 
they had not felt the necessity of using the therapy for their patients. But there where are also 
a lot of answers that suggested to wait for more studies of safety and efficacy. There was also 
answers that implicated that they were waiting for their national medical products agency to 
approve the medications first. The ones that had prescribed cannabinoid products, had mostly 
prescribed CBD oil, or Epidiolex®. The indications on which they had prescribed cannabis 
products is shown in Figure 4. 
Perceived among caregivers that had prescribed cannabinoids is shown in Table 4. We also 
asked for adverse effects when prescribed cannabinoids, and lethargy/drowsiness and 
gastrointestinal symptoms e.g. diarrhoea and vomiting where the most frequent.  
Finally, we aimed to ask the caregivers how they appreciate that the “climate” is for 
these substances. Forty-nine out of 71 have had patients or family of patients requesting 
cannabinoid therapy. Over 40 % of caretakers are aware of cannabinoid self-medication (not 
prescribed by a doctor). There were not many of caregivers that had prescribed cannabinoid 
therapy on any other indication than epilepsy.  
 
 
5. Discussion  
 
This review, was first intended to be a systematic review based on the PRISMA-P guidelines 
these last 5 years. We focused on 25 studies (eleven clinical studies, 9 animal and 
pharmacological studies and 5 survey studies) that matched the inclusion and exclusion 
criteria.  
 
In addition, there were over 20 reviews identified in our search and over 10 communications 
with anecdotal stories of cannabinoid efficacy (6, 13, 21, 24, 38-60). 
It could be argued that this is an indicator of cannabinoid treatment in epilepsy currently 
being a subject of intense current interest in its field. The public, through social media and 
news are becoming more and more aware of it. Clinical physicians, will increasingly have to 
answer questions and guide patients in the use of medical cannabis and consider the potential 





The studies were of heterogenous study methods. The RCTs showed postintervention 
reductions in the primary outcomes, and there were open-label trials that although lack of 
blinded control groups (which limits the quality of evidence) also reported results that agrees 
with the results from the RCTs. Secondary endpoints, which in a lot of the studies (clinical 
and surveys) comprises of different scales of measuring other benefits like quality of life, 
alertness, cognitive function also showed improvement.  
 
The animal, pharmacological studies have not proved the full mechanism in which CBD has 
reductive capacity in regard to seizures, but in vitro and in vivo models (which of course are 
not the same as in humans) the results speak for themselves.  
 
One thing that must be defined and taken into account is that in a lot of these studies there is 
not a standardised cannabis product. Most of researchers and clinicians agree that the 
composition of the product that ought to be used should be almost solely CBD. Some of the 
surveys and cohort studies do not discriminate between cannabis product and this gives a 
wrong perception of efficacy and adverse effects profile. The consensus seems to have 
evolved into being that CBD is the compound that has seizure reductive traits to it. Therefore, 
the continuance of this discussion we will focus on the CBD products (Epidiolex®, RSHO-X 
®, enriched-CBD oral solutions etc.)   
 
There are also many adverse events. The most common seem to be somnolence, diarrhoea, 
pyrexia, vomiting, decreased appetite. However, a lot of them seem to be mild or moderate in 
proportion, and in most cases, they get resolved by dose-control. 
 
There was however, some serious adverse events in CBD studies. One example is the drug-
drug interactions that it displayed with concomitant AEDs that patients took. Multiple studies 
have shown there is interactions between CBD and CLB (or it’s active metabolite N-
desmethylclobazam). This is due to CBD’s potent inhibition of CYP2C19, which is 
responsible for the metabolism of N-desmethylclobazam. One study also showed that CBD 
interacts with topiramate, zonisamide, eslicabazepine and rufinamide (26). In the cases of 
patients of these studies that used Valproate or some form of it, elevated levels of ALT/AST 
after CBD treatment became so serious that they discontinued CBD treatment. Researchers 




interactions. Nonetheless, patients seem to tolerate CBD well (23, 26). All these interactions 
need to be taken in account for if it in the future will be a possibility of treating PWE with 
CBD. However, like the surveys and other studies report, there is already a lot of people using 
some of these products and maybe their physician does not know about this, which can have 
terrible consequence.  
 
This leads us to another point, the AEDs. Pointed out earlier in this review, a lot of the 
patients with TRE have often tried out a lot of different combination and may medicate with 
several AEDs. Patients, and parents turn to other treatment options when these do not control 
the seizures or perhaps have terrible side-effects. Polypharmacy is a real struggle in this 
patient group. This is also reported as a reason why patients turn to cannabinoids (34). 
The decision-making process for families regarding use of cannabis products for the treatment 
of paediatric epilepsy is not well understood. Particularly in children with severe epilepsy, 
families may turn to nonstandard treatments out of frustration with conventional medications 
and therapies (3). 
 
In one of the survey, it was established a correlation of a stronger belief in the efficacy of 
CBD in patients with families that had relocated to a state were medical marijuana is legal. 
Parents who had relocated to Colorado were more than twice as likely to report a 50% 
reduction in seizures than were those who were long-time residents (47% vs 22%) (37) .This 
is a problem with all of these studies in general. The ones that report seizures and other results 
are human, and often parents, or people close to the patients. How big the subjective bias is, is  
hard to determine. The issue of the placebo response is especially relevant in paediatric trials 
of cannabis-derived treatments. A placebo effect is also more concerning with cannabis-based 
preparations than with other antiepileptic drugs because of the intense media and family 
interest in the compound. It could also be a result because of parental belief in cannabidiol 
benefits because of high expectations (10). What is seen in studies is that parental perception 
of benefit of OCEs on seizure profile is a key driver of continued use of OCEs. Because many 
of the studies are retrospective, recall bias is another issue (3).  
 
It is difficult to discern whether improved quality of life (QOL (which is reported in almost 




phycological benefits of reduced seizures, as each factor independently contributes to QOL, 
but the effects are not easily dissociable (21).  
 
Our survey gives us an impression of the situation in Norway, Sweden, Denmark and 
Germany. It seems to be that there are a lot of hinders for caregivers to prescribe CBD. To 
begin with almost half of the responders argue that there are no patients that are in need of the 
treatment. Another issue seems to be that there is no product available, but mostly they also 
warrant studies to prove safety and efficacy. However, a lot of caregivers have come into 
contact with patients/families that have requested CBD treatment. 
 
Limitations of the literature review is among others that the PRISMA guidelines were not 
fully met by this review (it can be argued that there were limitations to the study selection, 
summary measures and the risk of bias across studies). Lack of group for comparison and 
lack of blinding in most studies is also a big limitation.   
 
To our own survey the biggest limitation is the low response rate. Thus, we do not know 
whether the results are not very representative. One can speculate, that the Nordic countries 
might be a bit conservative and the topic is too progressive or controversial. Despite a low 
response rate, the issues that came up in our survey, are resonating in the literature. The 
research community is making progress though, since 2013 clinical studies have multiplied, 
and at present there are about 25 ongoing clinical trials studying the effect on seizure 
frequency of CBD-enriched products, as well as their safety and drug interactions (24). 
 
6. Conclusion 
Use of cannabis products, especially CBD seems to have an effect on seizure reduction, most 
shown in people with TRE. However, the results vary, and so far, there is not a good enough 
understanding of adverse event profile, or true efficacy. Still, people with TRE might not have 
very many options and for those cases CBD should absolutely be therapeutic option.    
Rigorous prospective placebo-controlled studies of CBD are needed, where it is also taken in 
account for these drug-drug interactions that have been shown and that there might be certain 
subgroups of epilepsy that benefit more than others. This thesis already misses out on new 




The result from our survey indicates that even though many of the responder had heard about 
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Tzadok et al. 2016 
Israel (20) 
Retrospective cohort, 
74 patients  
52% of cohort 29% / 18% Median of 5.5 months 
/ CBD:THC 2:1 
Rosenberg et al. 
2017, US(21) 
Prospective open 
label, 48 patients 
41,7% of cohort 58% / 20% 12 weeks / Epidiolex, 
CBD 
Gofsheteyn et al. 
2017, US (22) 
Prospective open 
label, 5 patients  
Was reported as 
collective 65% 
decrease in seizure 
frequency  
40% /- 48 weeks / Epidiolex, 
CBD 
Ladino et al. 2015 
Canada (61) 
Retrospective 
cohort,18 patients  
Was reported as 
decrease in seizure 
frequency of 54 %  
11% /-  6 months, Medical 
marijuana or street 
bought marijuana   
 
Table 2. Pharmacological and animal studies. 
Article, Country Hypothesis  
Research question 
Study design Intervention Results 
















expression for the 




levels in plasma.   
Patel et al. 2016, 
US (25) 
Is it possible to 
target resurging 
sodium current in 







of Sodium voltage 
channels and also 
if CBD had impact 
on them.  
Mutations were 
introduced in HEK2 
cells. The cells 
were with 
measurements of 
current where done 
Mutation Nav1.1 
that result in DS did 
not alter peak 
resurgent current. 
However, Nav1.6 





before and after 




resurgent current.  
Gaston et al. 2017, 
US (26)  
Are there 
interactions 




CBD was started in 
a group of 39 












Klein et al. 2017, 
US (27) 
Does CBD have 
protective traits in 
treatment resistant 
epilepsy.     
Evaluation of mice 
that were treated 
with CBD in 
regard to seizure 
protection.   
The mice/rats were 
induced in seizures 
and treated with 
CBD to the point 
they became 
seizure protected. 
(what dosage, but 
also different types 
of phases, acute or 
more chronic types 







Rowley et al. 2017, 
US (28) 
Does CBR have a 





mice with different 
setups of CBRs. 
Mice were created 
without CBR1 and 
CBR2 or without 
both and then 




seizures in CBR 
double knock-out 
mice was much 
more prevalent than 
in single CBR 
knockout mice.  
Huizenga et al. 
2017, US (29) 








redactors.   
DMCM3 was given 
to rats with 
treatment with 
either agonist or 
antagonists of 
CB1/2, CB1, CB2. 
The mixed CB1/2 








Di Maio et al. 
2015, US (30) 
Does treatment 




damage after SE   
Controlled trial, 
looking at the 
effects of WIN 
55,212-2 in rats 
with induced SE 
Different groups, 
two that received 
SE induction and 
one with WIN 
55,212-2 treatment.  









Carletti et al. 2015, 
Italy (31) 
What are the anti-
epileptic effects of 
WIN 55,212-2 and 
7NI5 
Controlled trial, 
looking at the 
effects of WIN 
55,212-2 and 7NI  







therapy with WIN 
55,212-1 or 7NI. 
Both WIN 55,212-2 
and 7NI proved 
their ability to 
modulate epileptic 
phenomena with a 
neuroprotective 
effect.  
Amada et al. 2013, 
UK (32) 




Controlled trial. Mice that were 
treated with CBDV 
were challenged 
with PTZ. 
The results provide 
the first molecular 
confirmation of 
anticonvulsant 
effects by CBDV. 
 
1 qrt-PCR = quantitative real-time PCR  
2 HEK = Human embryonic kidney  
3 DMCM = methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate, a chemo-convulsant 
4 WIN 55,212-2 = An aminoalkylindole derivative, with effects similar to those 
of cannabinoids 
5 7NI = 7-Nitrodazole , a preferential neuronal nitric oxide synthase inhibitor 
6 CBDV = Cannabidivarin, another phytocananbinoid  













Table 4. International survey: Caregiver’s perceived efficacy, among those who had 
















Figure 1. An overall classification model, taken from Fisher et al. 2017. 
 
 







Figure 3. International survey: Why caregivers had not prescribed cannabis products.  
 
 
Figure 4. International survey: What indication cannabis products have been prescribed by the 




10. Attachment “ International survey on cannabinoid 
treatment of epilepsy in children” 



















































11. Summary of study design quality of the main 




Reference:  Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, et al. Trial of 
Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. New England 
Journal of Medicine. 2017;376(21):2011-20. 
GRADE 
Class of Evidence (CoE) II 
Recommendation B 
Purpose Material and method Results Discussion/commentaries 
   The trial 
consisted of one 





group.   
Study sign:  
The study was a 
multinational, randomized, 
double-blinded phase III 
trial.  
Inclusion criteria: 
The population were young 
adults 2-18 years old that 
had Dravet syndrome with 
seizures that were not under 
control by their current 
antiepileptic drug regimen 
Exclusion criteria: 
Clinically significant 
unstable medical conditions 
other than epilepsy. Past 
recreational or medical 
cannabis use.  
Randomization process: 
The randomization process 
is not revealed in the paper, 
but it is explained in the 
appendix protocol. An 
independent statistician 
produced randomization 
schedules, that were not 
divulged before unblinding. 
Blinding:  
The CBD solution and 
placebo solution were 
identical to the cannabidiol 
solution excepts for the 




The characteristics of the 
trial groups were similar at 
baseline of the study. The 
placebo solution was 
identical to the CBD 
solution except for the 
absence of CBD. They were 
treated in and had the same 
routine protocols.   
In a figure it is presented 
that 9 patients in the CBD-
group and 3 in the placebo 
group. The reasons of 
withdrawal are described. 
Out of the 108 patients who 
completed the study 108 
entered an open-label study.       
Primary and secondary endpoints were 
identified. 
Primary results: 
   The results of the primary efficacy 
endpoint were presented like difference in 
percentage of the median number of 
convulsive seizures per month. The adjusted 
median difference in convulsive seizures 
between the CBD group and the placebo 
group was -22,8 percentage points (95% 
[CI], -41,1 to -5,4; P=0,01).  
Secondary results: 
When continued onward to secondary 
endpoints the reduction in convulsive-
seizure frequency by 50 % or more during 
the treatment period occurred in 43% of the 
patients in the cannabidiol group and in 27 
% of the patients in the placebo group (odds 
ratio 2.00; 95% [CI], 0,93 to 4.30; P=0,08). 
During the treatment period 3 patients in the 
cannabidiol group and no patients in the 
placebo group were free of seizures 
(P=0,08). All the endpoints were measured 
and presented.  
   The results are representative and 
applicable in clinical situations if you 
consider the population.  
 
    
It was approved by the review board or 
ethics committee at each participating 
institution and was conducted in accordance 
with the principles of the Declaration of 
Helsinki and the International Conference on 




Adverse effect where more prominent in the 
CBD group compared with the placebo 
(93% vs. 75% of the patients). Among 
patients with adverse events, 89 % had 
events that were mild or moderate in 
severity (84% in the CBD group and 95 % in 
the placebo group). There were however 
some serious adverse events (10 patients in 
the cannabidiol group and 3 in the placebo 
group). SE was reported in 3 patients in each 
group. Elevated levels of liver 
aminotransferase enzymes led to the 
withdrawal from the trial for 3 patients in 
the CBD group and 1 in the placebo group. 
All these patients were taking some form of 
valproate.  
 
   As for limitations of the study, the 
founding source of the trial, GW 
Pharmaceuticals, was responsible for the 
trial design, (with input from investigators 
and other experts) trial management, site 
monitoring, trial pharmacovigilance, data 
analysis, and statistical analysis. GW 
Pharmaceuticals prepared and provided the 
active treatment and placebo. 
Another potential limitation to this partially 
subjective endpoint of convulsive-seizures 
frequency reported by caregivers is that the 
side effects of the drug being tested might 














are needed to 
determine the 
long-term efficacy 
and safety of 
cannabidiol . 
Country 
 23 centres in the 
U.S. and Europe 







 Confounders:  
CBD interactions with other 
AEDs.  
Statistic methods: 
A Wilcox rank-sum test is 
used to analyse the primary 
endpoint. An estimate of the 
median difference between 
CBD and Placebo was 
calculated with the Hodges-








Reference: Thiele EA, Marsh ED, French JA, Mazurkiewicz-Beldzinska M, Benbadis SR, Joshi C, et al. 
Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a 
randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10125):1085-96. 
GRADE 
Class of Evidence (CoE) II 
Recommendation B 
Purpose Material and method Results Discussion/commentaries 
Assessing the 
efficacy and safety 










dosage issue and 




This study is a randomised, 
double-blinded, placebo 
controlled, phase III  
Inclusion criteria: 
Eligible patients were aged 
between 2 and 55 years, with 
a defined clinical diagnosis 
of Lennox-Gastaut. 
Exclusion criteria: 
Patients with clinically 
unstable illness (other than 
epilepsy), history of alcohol 
or substance abuse, 
recreational or medical 
cannabis users or had taken 
corticotrophins in the 
previous 6 months.  
Randomization: 
The randomisation schedule 
was produced by an 
independent statistician. 
Blinding: 
All patients, caregivers, 
investigators, and 
individuals assessing data 
were masked to group 
assignment. Both 
cannabidiol and placebo 
were provided in identical 
100 mL amber glass bottles 
and could not be 
distinguished visually. 
Data base: 
The two treatment groups 
had similar patient 
demographics and baseline 
characteristics. 
171 were randomized (86 = 
CBD group and 85 = 
placebo group).    
Confounders:  
Drug-drug interactions 
between CBD and other 
AEDs. Hard to differentiate 
how much of the anti-
convulsive effect is 
primarily from CBD.  
Statistic methods: 
The primary endpoint was 
assessed with a Wilcoxon 
rank-sum test, and the 
estimated median difference 
(with 95% CI) between the 
Primary results: 
The primary endpoint was the percentage 
change in monthly frequency of drop 
seizures from baseline, measured during the 
14-week treatment period.  
The estimated median difference between 
the treatment groups was -17,21 (95% CI –
30,32 to –4,09; p=0,0135) during the 14-
week treatment period and –19,45 (-33,05 to 
–4,68; p=0,0096) during the 12-week 
maintenance period alone. Since the primary 
endpoint reached statistical significance, 
formal statistical analysis of the key 
secondary endpoints was permitted. 
Secondary results:  
The key secondary endpoints were the 
proportion of patients in each treatment 
group that achieved a reduction of 50% or 
more in monthly frequency of drop seizures. 
3 patients who were in the cannabidiol group 
and completed treatment were drop seizure 
free throughout the 12-week maintenance 
period. No patients in the placebo group 
were free of drop seizures. Also, the total 
amount of seizures in the cannabidiol group 
decreased more in comparison with the 
placebo group. The estimated median 
difference was –21,1 (95 % [CI]  –33,3 to –
9,4; p = 0,0005) during the treatment period 
and –23,3 (95% [CI] –36,3 to –10,5; p = 
0,0004) during the 12-week maintenance 
period.  
 
Caregivers  Global Impression of Change 
(GIC) in seizure duration, and change in 
sleep disruption and daytime sleepiness, 
quality of life, and adaptive behaviours. 
There were 3 times as many 
patients/caregivers in the cannabidiol group 
than the placebo group reporting their 
overall condition as very much improved (15 






The study protocol was developed in 
accordance with the Declaration of Helsinki 
and the Good Clinical Practice guidelines 
and approved by the institutional review 
board or independent ethics committee for 
each study site. 
Patients or caregivers recorded the number 
and type of seizures, including drop 
seizures, each day using an Interactive Voice 
Response System (IVRS). Patients or 
caregivers recorded information on study 
drug use, concomitant medications, and 
adverse events in a paper diary. Patients who 
completed treatment were eligible to enrol in 
an open-label extension trial. 
Common adverse effects (that occurred in 
more than 10 % of patients) in the 
cannabidiol group were diarrhoea, 
somnolence, pyrexia, decreased appetite, 
and vomiting. Of the patients who had all 
cause adverse events, the events resolved by 
the end of the trial in 45 ( 61%) patients in 
the cannabidiol group and 38 (64%) patients 
in the placebo group.  
 
There are some limitations of this study, the 
funding of the study came from GW 
pharmaceuticals.  
There are unmistakably drug-drug 
interactions and the potential of CBD and 
Valproate and Clobazam should be 
additional investigated.  
The use of subjective scales (GIC). 
The population of the trial (90% Caucasian) 




In this RCT with 
Lennox-Gastaut 
syndrome patients 
treated with CBD 
there was a 
significant 
reduction in 
frequency of drop, 






The trial took 
place at 24 clinical 
sites in the USA 
(n=17), the 
Netherlands (n=1), 










cannabidiol and placebo 




According to the statistical 
analysis plan, if the primary 
endpoint was met (i.e., 
statistical significance was 
reached), the key secondary 
endpoints were to be tested 















Reference:   1. Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. Cannabidiol 
as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. 
2016;57(10):1617-24. 
GRADE 
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To evaluate 
efficacy, safety 
and tolerability of 
CBD, as an 
adjunct to current 
AEDs in patients 
with refractory 







This was a prospective cohort 
study 
Inclusion criteria: 
To be eligible for the study a 
diagnosis of TSC (Tuberous 
sclerosis complex) was required, 
as well as treatment-resistant 
epilepsy, using between 1-7 
AEDs at stable doses for a 
minimum of 2 weeks, stable 
vagus nerve stimulation settings, 
and stabile  ratios for ketogenic 
diet of minimum 4 weeks. 
Exclusion criteria: 
Allergies to ingredients in the 
study drug solution, use of 
cannabinoid therapy within 4 
weeks before start of study, 
pregnancy, unstable hepatic, 
hematologic, renal, 
cardiovascular, gastrointestinal or 
pulmonary disease 
Data base: 
There were 18 patients that 
enrolled  with TSC. 
9 of the 18 TSC patients were 
male and so the other 9 females. 
The age range between 2-31 with 
an average of 14 years. 10 (55%) 
of the 18 patients underwent 
neuro-psychological testing, of 
whom 6 (60%) were cognitively 
impaired (IQ< 70). 
The median total weekly seizure 
frequency during the 4-week 
baseline period was 22 (IQR 
14,8-57,4).   
Confounders:  
Drug-drug interactions occurred 
but were handled with reduction 
in dosing of AEDs. 
Statistic methods: 
 Using a percentage change in 
seizure frequency at each time 
point, (2nd, 3rd, 6th, 9th, and 
12th month), patients were 
defined as responders if they had 




The median total weekly seizure 
frequency decreased to 14,9 ( IQR 5,7-
22,0) after 2 months treatment, 13,2 
(IQR 5,06-22,1) after 3 months of 
treatment, 9,7 after 6 months and 7,7 
after 9 months and 8,0 after 12 months 
of treatment 
Secondary results: 
 After 3 months of treatment with CBD, 
four patients had a percent decrease in 
seizures of >80 %, and 2 patients had a 
decrease greater than 90 %. After 3 
months of treatment with CBS, the 
median weekly seizure frequency 
decreased for all seizure types 
experienced by patients in the study. 
Based on calculated median percent 
changes in seizure frequencies after 3 
months the greatest reduction in 
seizures was observed in tonic-clonic 
seizures (-91,4 % ), followed by 
epileptic spasms (-87,5%), atonic 
seizures (-86,5%), complex partial 
seizures (-59,3%), tonic seizures (-
48,2%) and complex partial seizures 
with secondary generalization ( -
38,6%).  
 
Comment: Patients who exited the 
study before a certain time point or 
patients who lacked follow-up to a 
given time point were not included in 







The patients consented to the IRB 
(institutional review board) and FDA 
approved expanded-access study of CBD 
under Investigational New Drug (IND).  
 
12/18 patients in this study experienced at 
least one adverse event thought possibly 
could be related to CBD. Most adverse 
events experienced in this study were 
temporary and of mild severity. Adverse 
events were resolved through dose 
adjustments of CBD or concomitant 
antiepileptic drugs. 
 
At each clinic visit, patients or parents 
returned logs of recorded seizures since the 
last clinical visit. Changes in the dose of 
concomitant AEDs were made as clinically 
indicated. After third month of CBD 
treatment, doses of CBD and concomitant 
AED were changed monthly in nearly all 
patients in order to optimize seizure control.  
 
Limitations for this study is that it did not 
include a control group and was of small 
size. Then there is also the question of 
subjectivity in the reporting of seizures and 
how accurate those are.  
Conclusion 
In this study many 





with CBD as an 
add-on to their 
treatment regime. 
Country 
 U.S.  
 







Reference: Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, et al. Cannabidiol in 
patients with treatment-resistant epilepsy: an open-label interventional trial.[Erratum appears in 
Lancet Neurol. 2016 Apr;15(4):352; PMID: 27302053]. Lancet Neurology. 2016;15(3):270-8. 
GRADE 
Class of Evidence (CoE) III 
Recommendation B 
Purpose Material and method Results Discussion/commentaries 
To establish 
wheter addition of 
CBD to existing 
anti-epileptic 
regimens would 
be safe, tolerated 
and efficacious in 
children and 







open label trial. 
Inclusion criteria: 
Patients that had severe, 
childhood-onset and 
treatment-resistant epilepsy 
and had four or more 
countable seizures with a 
motor component per month 
and received stable doses of 




ketogenic or modified 
Atkins diet, had to have the 
ratio of fat to carbohydrate 
and protein stable for 4 
weeks before enrolment. 
Similarly, individuals with a 
vagus nerve stimulation, 
settings had to be stable for 
minimum 4 weeks. 
Study-wide exclusion 
criteria included previous or 
current treatment with 
cannabis-based therapy. 
Data base: 
Patients at all sites were 1-
30 years of age. The most 
common epilepsy 
syndromes treated were 
Dravet syndrome and 
Lennox-Gastaut syndrome. 





Multiple logistic regression 




GW Pharmaceuticals who 
also provided the treatment 
product had no role in study 
design, data analysis, data 
interpretation, or writing of 
the report.  
 
 
162 patients (76%) had at least 12 weeks of 
follow-up  after the first dose of cannabidiol. 
The primary endpoint was to establish the 
safety and tolerability of cannabidiol, and 
the primary efficacy outcome was median 
percentage change in the mean monthly 
frequency of motor seizures at 12 weeks. For 
the second efficacy analysis the median 
percentage change in other seizure types, 
including tonic, atonic, tonic-clonic, focal 
non-motor, and total seizures was assessed.  
   
Primary results: 
 The median change in total seizures was –
34,6% (IQR –66,7 to –9,8), with the greatest 
reduction occurring in patients with focal 
seizures or atonic seizures, followed by tonic 
seizures or tonic-clonic seizures. 
Secondary results: 
 Analysis of the secondary endpoints of 
responder rates showed that 54 (39%) 
patients had a reduction of 50% or more 
motor seizures, whereas 29 (21%) had a 
reduction of  70% or more and 12 (9%)  had 
a reduction of 90% or more. Two patients 
were free of all seizure types over the entire 
12 weeks. All results are well presented. 
Because each of the 11study sites applied for 
their own investigational new drug 
registration for the expanded-access 
programme, there was some variability in 
eligibility criteria between centres.  
All seizures were recorded by parents or 
caregivers on paper diaries and reviewed by 
the study team at each clinical visit. 
Tolerability and adverse effects were 
assessed every 2 weeks by use of the 
Liverpool Adverse Events Profile or the 
Paediatric Epilepsy Side Effects 
Questionnaire, depending on age.  
 
Reasons for withdrawal included allergy to 
the sesame oil vehicle, hepatotoxicity, 
excessive somnolence and poor efficacy, 
gastrointestinal intolerance, worsening 
seizures, and hyperammonaemia 
 
Most adverse events were mild or moderate 
and transient. Serious adverse events were 
reported in 48 (30 %) patients. Serious 
adverse events deemed possibly related to 
cannabidiol use were recorded in 20 patients 
and included status epilepticus, diarrhoea, 
pneumonia, and weight loss. 11 (7%) 
patients had elevated liver function tests, one 
patient had a significant increase in 
transaminases leading to discontinuation of 
cannabidiol. The adverse event profile of 
cannabidiol was favourable, with most 
patients tolerating the drug well despite its 
addition to a median of three concomitant 
antiepileptic drugs 
 
The major limitations of this story were that 
it was open label and uncontrolled. The 
issue of the placebo response is especially 
relevant in paediatric trials of cannabis-
derived treatments. Among findings from 32 
randomised controlled trials of add-on 
treatment in patients with epilepsy, children 
had a significantly higher response to 
placebo (19%)  than adults, whereas 
responder rates to the trial intervention were 
similar. A placebo effect is also more 
concerning with cannabis-based preparations 
than with other antiepileptic drugs because 
of the intense media and family interest in 
the compound.  
 
Conclusion 
The safety and 
tolerability was 
acceptable, with 
only five (3%) out 
of 162 patients 
stopping treatment 




however RCTs are 
needed to 
characterise the 
safety profile and 
true efficacy.  
Country 
 11 epilepsy 
centres across the 
USA 
Year of data 
collection 








Reference:   Treat L, Chapman KE, Colborn KL, Knupp KG. Duration of use of oral cannabis extract 
in a cohort of pediatric epilepsy patients. Epilepsia. 2017;58(1):123-7. 
GRADE 
Class of Evidence (CoE) III 
Recommendation C 
Purpose Material and method Results Discussion/commentaries 
The purpose of 
this study was to 
measure the 
duration of use 
and perceived 
efficacy of Oral 
Cannabis Extracts 
(OCEs) in a 





Study sign:  
Retrospective cohort, 
medical chart review. 
Inclusion criteria:  
Patients were included in 
this study if they carried a 
diagnosis of epilepsy and 
had a documented seizure 
frequency, both before and 
after initiation of OCEs. The 
participants included were 
from 30 days to 18 years of 
age. 
Exclusion criteria: 
Nondaily use of OCEs, or if 
OCEs were used for reasons 
other than seizure control. 
Data base: 
Sample size 119.   
Confounders:  
Bias of patients that had 
relocated til Colorado 
seemed to overreport 
efficacy of treatment 
Statistic methods: 
Multiple Cox proportional 
hazard (PH) model, Fisher’s 










Epilepsy syndrome and seizures types were 
recorded as documented by the treating 
clinician, according to the ILAE 
classification. 
Seizure response was based on a parental 
report of seizure frequency prior to initiating 
ICEs compared to the last documentation of 
seizure frequency while on OCEs.  
 
Patients were considered responders to 
OCEs if parents reported a > 50 % reduction 
in seizure frequency.  
Primary results: 
The parents of 58 patients (49%) reported at 
least some improvement in seizures. 24% of 
the cohort were considered to be responders 
to OCE treatment.  
Secondary results: 
   Lennox-Gastaut syndrome (LGS) was the 
only syndrome type associated with a 
significantly higher proportion of responders 
when compared to all other patients in the 
cohort: 11 (58%) of 19 patients (p < 0.05).  
 Perception of any seizure benefit was the 
only factor significantly associated with 
longer duration of OCE use ( p <0,01). 
   Only Dravet syndrome emerged as 
significantly impacting duration of OCE use, 
and the presence of this diagnosis was 
associated with a shorter duration (p = 0.02) 
   Relocation to Colorado was associated 
with perceived benefit of OCEs (65% vs 
38% p=0,01), but was not independently 
associated with longer use of OCEs. 
    Non-seizure benefits were also reported, 
including improved behaviour/alertness in 
46 patients (39%), improved motor skills in 




   Of the 119 patients included, 41% had 
relocated with their families to Colorado 
prior to starting OCEs. Patients were 
considered to have moved to Colorado for 
OCEs if evidence of this relocation was 
documented in the electronic record. 
 
An interaction between relocation to 
Colorado and perception of seizure benefit 
was not significant, so it was excluded from 
the multiple Cox PH model. 
 
The most common AEs included worsening 
of seizures in 10 patients (8%), somnolence 
in 7 (6%), and gastrointestinal symptoms in 
6 (5%). Eighty-four patients (71%) 
discontinued their OCE use during the study 
period. 
  
What is seen in the study is that parental 
perception of benefit of OCEs on seizure 
profile is a key driver of continued use of 
OCEs. The relocation to Colorado for usage 
of OCEs has been shown to predict parental 
perception of benefit. This suggest that 
sociologic factors may also play a role in 
medical decision making about OCEs.  
 
    
   There are limitations to this study, like the 
recall bias on behalf of the parental report. 
The alterations of prescribed AEDs. The 
non-discrimination of different OCEs The 
available information on the retrospective 









benefit is a key 
driver of 
continued OCEs,  
Remarkably, at 
least one third of 
patients who did 
not experience any 
seizure benefit 
continued to use 
OCEs at last 
follow-up, which 
could reflect use 






Year of data 
collection 
2013- 2015 
